Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients

Tel-Aviv Sourasky Medical Center50 enrolled

Overview

Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress. The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes

Interventions

Blood withdrawalPROCEDURE

This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Un balanced diabetic patients. Exclusion Criteria: * No current infection.

Locations (1)

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

RECRUITING

Outcomes

Primary Outcomes

Levels of gene expression for UCP2 (RQ)

Checking UCP2 levels compared to HgBA1c

Time frame: 6 months

Secondary Outcomes

Improved metabolic state

Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).

Time frame: 6 months

Central Contacts

Nachum Vaisman, MD

CONTACT

972-3-6974807 vaisman@tasmc.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.